Q3 2024 Ajanta Pharma Ltd Earnings Call Transcript

Jan 31, 2024 / 11:30AM GMT
Operator

Ladies and gentlmen, good day and welcome to Ajanta Pharma Q3 FY24 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you and over to you, sir.

Yogesh Agrawal – Ajanta Pharma Ltd – Managing Director, Executive Director

Thank you. Good evening, everyone, and welcome to this earnings call. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO; and Mr. Rajeev Agrawal, our EVP, Finance and Investor Relations.

I hope that the results are already there with you. We will take you through the business-wise performance for the Q3 and nine months of the current year, along with the comparison of previous year same period.

I am pleased to inform you that the Board of Directors have approved the second interim dividend for the current year. The share of INR2 face value will receive a dividend of INR26 amounting to the dividend amount of INR327 crore. In